Operating Costs and Expenses. All available records of any operating costs and expenses for the Property in Seller’s possession.
Operating Costs and Expenses. Operating costs and expenses for the dock and buoy such as power and water utilities, repairs and maintenance, taxes and insurance, and other expenses relating to the dock and buoy shall be paid by the Manager and reimbursed as designated in paragraph 4. The Manager will keep accurate accounting records of the ongoing operating costs and make the accounting records available upon request of any Party.
Operating Costs and Expenses. The Owners shall be charged for, and shall pay, their share of the expenses, as authorized by FAR Part 91.501(c)(3), according to xxxxxxxx (as described in Section 7 below) prepared by ALLETE in its management role, for all ownership and operating costs and expenses for the Aircraft. Such ownership and operating costs and expenses include:
Operating Costs and Expenses. 3.2.1 Subtenant shall pay to Sublandlord as additional rent hereunder Subtenant’s pro rata share of (i) Tenant’s Share of Direct Expenses (as defined in the Master Lease) payable by Sublandlord under the Master Lease, and (ii) utilities (including any applicable taxes thereon) contracted through Sublandlord. Subtenant’s pro rata share shall mean that amount, expressed as a percentage, equal to the number of square feet included in the Premises then subleased by Subtenant divided by the number of square feet leased by Sublandlord under the Master Lease (i.e., 74.27% prior to the prior to the Expansion Premises Commencement Date, and 100% after the Expansion Premises Commencement Date). Such amounts of Direct Expenses shall be payable in advance on the first day of each calendar month during the Term of this Sublease in accordance with Article 4 of the Master Lease. Sublandlord shall promptly forward all Estimate Statements, Statements, invoices and backup documentation received from Master Landlord regarding Tenant’s Share of Direct Expenses. Subtenant shall be entitled to all credits, if any, given by Master Landlord to Sublandlord for Sublandlord’s overpayment of any amounts under the Master Lease to the extent allocable to the portion of the Premises as to which this Sublease has commenced and to the extent paid by Subtenant. In the event that the Term shall expire or earlier terminate on any date other than December 31, Subtenant’s obligations under this Section 3.2.1 for such calendar year shall be prorated on the basis of the number of days elapsed during such calendar year prior to and including the date of expiration or termination.
Operating Costs and Expenses. The Partnership shall (i) pay, or cause to be paid, all costs, fees, operating expenses and other expenses of the Partnership (including the costs, fees and expenses of attorneys, accountants or other professionals and the compensation of all personnel providing services to the Partnership) incurred in pursuing and conducting, or otherwise related to, the activities of the Partnership, and (ii) in the sole discretion of the General Partner, reimburse the General Partner or any member of the Executive Committee or any employee of the Partnership for any out-of-pocket costs, fees and expenses incurred by them in connection therewith. Since the General Partner is the general partner of the Partnership and provides a means through which Class B Partners may exchange their Class B Units for securities of the General Partner, the General Partner may cause the Partnership to pay or bear all expenses of the General Partner, including, without limitation, costs of securities offerings not borne directly by Class B Partners, Board of Director compensation and meeting costs, costs of periodic reports to its stockholders, litigation costs and damages arising from litigation, accounting and legal costs and franchise taxes, provided that, without limiting the rights of the General Partner to receive distributions pursuant to Sections 4.1 and 4.2, the Partnership shall not pay or bear any income tax obligations of the General Partner pursuant to this Section 4.7.
Operating Costs and Expenses. 3.2.1 Subtenant shall pay to Sublandlord as additional rent hereunder Subtenant’s pro rata share of (i) Operating Expenses (as defined in the Master Lease) payable by Sublandlord under the Master Lease, and (ii) utilities (including any applicable taxes thereon) contracted through Sublandlord. Subtenant’s pro rata share shall mean that amount, expressed as a percentage, equal to the number of square feet included in the Premises divided by the number of square feet leased by Sublandlord under the Master Lease [i.e., 86.46%]. Such amounts of Operating Expenses shall be payable in advance on the first day of each calendar month during the Term of this Sublease in accordance with Section 9.3 of the Master Lease. Sublandlord shall promptly forward the appropriate invoices and backup documentation received from Master Landlord regarding such Operating Expenses. In the event that the Term shall expire or earlier terminate on any date other than December 31, Subtenant’s obligations under this Section 3.2.1 for such calendar year shall be prorated on the basis of the number of days elapsed during such calendar year prior to and including the date of expiration or termination.
Operating Costs and Expenses. All available records of any operating costs and expenses for the Property in the possession of Seller which are not considered by Seller to be proprietary.
Operating Costs and Expenses. The Company's cost of product sales relates to VISTIDE and was $0.1 million for each of the quarters ended June 30, 1999 and 1998. Cost of product sales for the six-month periods ended June 30, 1999 and 1998 was $0.2 million and $0.3 million, respectively. Presently, cost of product sales is not a significant operating cost of the Company. R&D expenses for the second quarter of 1999 were $18.2 million, compared to $18.3 million for the same period in 1998. R&D expenses for the six-month periods ended June 30, 1999 and 1998 were $34.0 million and $37.3 million, respectively. These expenses decreased slightly in the 1999 periods relative to 1998 because of Gilead's reduced level of involvement in the development of Tamiflu, offset in part by greater levels of expense in 1999 for the development programs for adefovir dipivoxil for hepatitis B and tenofovir disoproxil fumarate (PMPA oral prodrug) for HIV. The Company expects its R&D expenses to increase during the remaining quarters of 1999 relative to 1998, reflecting increased expenses related to clinical trials for several product candidates as well as related increases in staffing and manufacturing process development. Selling, general and administrative ("SG&A") expenses were $7.9 million and $8.4 million for the quarters ended June 30, 1999 and 1998, respectively. For the six-month periods ended June 30, 1999 and 1998, SG&A expenses were $15.7 million and $15.2 million, respectively. The Company expects its SG&A expenses will increase during the remainder of 1999 over 1998 expense levels, primarily to support the increased level of R&D activities and, to a lesser extent, to support the expansion of sales and marketing capacity in anticipation of the potential launch of adefovir dipivoxil, an investigational reverse transcriptase inhibitor currently being studied to treat HIV. Merger related expenses attributable to the Company's merger with NeXstar were $0.7 million for the quarter ended June 30, 1999 and $1.3 million for the six months then ended. Merger-related expenses incurred to date are primarily for professional services and other merger-related fees. The Company will recognize significant one-time merger-related expenses related to the closing of the NeXstar merger in the third quarter of 1999. NET INTEREST INCOME The Company had net interest income of $3.3 million and $5.0 million for the quarters ended June 30, 1999 and 1998, respectively. Net interest income earned during the six-month periods...
Operating Costs and Expenses. For the quarter ended March 31, 1996, the Company's research and development expenses increased 16% to $9.3 million from $8.1 million for the same period in 1995. This increase was due primarily to increases in research and development staffing, preclinical expenses and expenses associated with the Company's ongoing clinical trials for several product candidates. The Company expects its research and development expenses in the remainder of 1996 will grow significantly reflecting anticipated increased expenses related to additions to staffing, preclinical studies, clinical trials and manufacturing. Selling, general and administrative expenses were $4.8 million and $2.8 million for the quarters ended March 31, 1996 and 1995, respectively, representing an increase of 75%. This increase was incurred to support the Company's establishment of marketing and sales capabilities in advance of potential product launch and to support the expanded research and development efforts, as well as to expand corporate development activities and related legal expenses and patent activities. The Company expects its selling, general and administrative expenses to significantly increase during the remainder of 1996 in connection with the establishment of sales and marketing capability in anticipation of potential product sales, related commercialization efforts and corporate development activities. NET INTEREST INCOME The Company had net interest income of $2.6 million and $1.0 million for the quarters ended March 31, 1996 and 1995, respectively, representing an increase of 153%. Net interest income has significantly increased due to the Company's higher average cash and cash equivalents and short-term investment balances which resulted from the Company's two public offerings of common stock completed in February 1996 and August 1995. LIQUIDITY AND CAPITAL RESOURCES Cash and cash equivalents and short-term investments were $303.8 million at March 31, 1996 compared to $155.7 million at December 31, 1995. This increase is the result of the Company's public offering of common stock in February 1996 which generated $155.6 million in net proceeds. No significant construction or build-out costs or other significant capital expenditures are expected to be incurred during 1996. During 1996, the Company expects to incur substantial research and development and selling, general and administrative expenses, including expenses related to additions to staffing, preclinical studies, clinical t...
Operating Costs and Expenses. The Board of Managers shall determine the amounts to be charged to each Shareholder in such manner and formula as the Board deems appropriate to cover all operating costs and expenses associated with the Shareholder s’ use of the System, including the costs of acquiring or leasing computer hardware, licensing the Software, administering and hosting the System using Company employees or third party consultants or vendors, generating and maintaining appropriate reserves, payment of principal and interest on any loans made to the Company, and any other expenses associated with the conduct of the Company’s business as authorized by this Agreement or resolution of the Board of Managers. The amounts determined by the Board of Managers to be charged to Shareholders to cover the operating costs and expenses of the Company, build adequate cash reserves and set asides for investing in approved strategic initiatives.
